This review outlines strategies for the identification and management of hyperlipidaemia to reduce cardiovascular risk.
Consolidates hyperlipidaemia management strategies for CV risk reduction; leaves open the need for prospective validation of optimal approaches.
SUMMARY Hyperlipidaemia is acknowledged as the major risk factor for coronary heart disease and atheroma progression. This review considers the strategies that should be followed to reduce overall cardiovascular risk in patients with hyperlipidaemia and deals with the identification and management of treating both polygenic and monogenic lipid disorders in the presence or absence of overt cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Anthony S. Wierzbicki (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: